Overview

A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder.

Status:
Completed
Trial end date:
2018-02-17
Target enrollment:
Participant gender:
Summary
The study evaluates the long-term efficacy and safety of SM-13496 in patients with bipolar I disorder.
Phase:
Phase 3
Details
Lead Sponsor:
Sumitomo Dainippon Pharma Co., Ltd.
Treatments:
Lurasidone Hydrochloride